COMPARE · Data as of August 24, 2026
DXCM vs RDNT
Verdict: Side-by-side breakdown using the Bull Rankings model. DXCM scored 77.3, RDNT scored 56.1 — DXCM leads.
Compare another set
DXCM
DexCom, Inc.
77.3
$91.06 · $34.4B
fundamentals as of
Score gap
21.2
DXCM leads
RDNT
RadNet, Inc.
56.1
$74.69 · $5.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthRDNT+18.9%
- Strongest balance sheetDXCM0.53
- Highest qualityDXCM91 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
DXCM
stronger →← stronger
RDNT
91
Qualityreturns · margins · balance sheet
35
89
Growthrevenue & earnings expansion
86
57
Valuevaluation vs sector peers
58
DXCM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
DXCM
RDNT
$1.4bC+
FCF
$236mC
+15.5%B+
Rev
+18.9%B+
0.53B
D/E
1.57C
36.0xC+
P/E
—
1.74C+
PEG
0.96B+
—
P/S
2.6xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
DXCM
RDNT
62% above
Price vs fair valuelower is cheaper
39% above
~24%/yr
Growth the price implies10-yr FCF · lower = less priced in
~24%/yr
-48%
1-yr DCF upside
-45%
-38%
5-yr DCF upside
-28%
-21%
10-yr DCF upside
+5%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DXCM
Why this score
- Buying back stock
- Durable high returns
RDNT
Why this score
- Diluting shareholders
The companies
DXCMDexCom, Inc.
Why now
Medical Devices · market cap $34.4b. Trading near 52-week high of $92.59 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $94.12 (implying +3% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
RDNTRadNet, Inc.
Why now
Diagnostics & Research · market cap $5.9b. 13% off the 52-week high of $85.84. Revenue growing +19%, comfortably above the S&P median. PEG 0.96 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $92.88 (implying +24% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -0.9%) — path to GAAP profitability is the core thesis risk. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where DXCM and RDNT diverge
On the headline score the gap is 21.2 points in favor of DXCM. The widest single difference is Quality, where DXCM leads by 55.4 points.
- QualityDXCM 90.6 · RDNT 35.2DXCM +55.4
- GrowthDXCM 89.5 · RDNT 86.5DXCM +3.0
- ValueDXCM 56.9 · RDNT 58.1level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.